Faes Farma, S.A. is engaged in the research, development, manufacture, marketing, and sale of pharmaceutical products and raw materials in Spain, Portugal, and internationally. The company offers prescription, OTC, and skin-care treatment products. Its products include Bilastine, a non-sedating antihistamine for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria in adults and children; F-97013-GD, an antipsychotic product, which is in pre-clinical phases; F-98214-TA, an antidepressant that is in pre-clinical phases; and Serotonin reuptake inhibitors. The company also manufactures raw materials, such as diosmin, hidrosmin, magnesium pidolate, and arginine aspartate, as well as granulated diosmin, glutodine, trimethropim, and pyrrolidone carboxylate. Faes Farma, S.A. was founded in 1933 and is headquartered in Bilbao, Spain.
faes farma sa (FAE:Continuous)
Avenida Autonomía, 10
Phone: 34 94 481 83 00
Fax: 34 94 481 83 01www.faes.es
|Recordati SpA||€12.58 EUR||+0.27|
|Salix Pharmaceuticals Ltd||$131.81 USD||-2.03|
|Shire PLC||4,870 GBp||+270.00|
|Procter & Gamble Co/The||$81.16 USD||-0.45|
|View Industry Companies|
Sponsored Financial Commentaries
To contact FAES FARMA SA, please visit www.faes.es. Company data is provided by Capital IQ. Please use this form to report any data issues.